Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Share Class Description:
WBO:REGN: Ordinary SharesTotal Employee Number:
15,410Compare
Compare
Traded in other countries / regions
REGN.USAREGN34.Brazil0R2M.UKRGO.GermanyREGN.MexicoREGN.Austria1REGN.Italy IPO Date
2017-05-22Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.2 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.62 | |||||
Interest Coverage | 75.34 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.39 | |||||
Beneish M-Score | -2.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.2 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | -0.5 | |||||
3-Year FCF Growth Rate | 5 | |||||
3-Year Book Growth Rate | 12.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.85 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.3 | |||||
9-Day RSI | 77.4 | |||||
14-Day RSI | 74.66 | |||||
3-1 Month Momentum % | -7.98 | |||||
6-1 Month Momentum % | -14.97 | |||||
12-1 Month Momentum % | 18.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.76 | |||||
Quick Ratio | 3.34 | |||||
Cash Ratio | 2.44 | |||||
Days Inventory | 491.88 | |||||
Days Sales Outstanding | 137.85 | |||||
Days Payable | 460.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.47 | |||||
Dividend Payout Ratio | 0.08 | |||||
Forward Dividend Yield % | 0.5 | |||||
5-Year Yield-on-Cost % | 0.47 | |||||
3-Year Average Share Buyback Ratio | 1.2 | |||||
Shareholder Yield % | 3.97 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.86 | |||||
Operating Margin % | 26.87 | |||||
Net Margin % | 27.87 | |||||
EBITDA Margin % | 35.43 | |||||
FCF Margin % | 22.96 | |||||
OCF Margin % | 30.08 | |||||
ROE % | 13.94 | |||||
ROA % | 10.74 | |||||
ROIC % | 14.88 | |||||
3-Year ROIIC % | -13.62 | |||||
ROC (Joel Greenblatt) % | 55.03 | |||||
ROCE % | 14.92 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 19.08 | |||||
Forward PE Ratio | 14.61 | |||||
PE Ratio without NRI | 16.42 | |||||
Shiller PE Ratio | 20.1 | |||||
Price-to-Owner-Earnings | 25.79 | |||||
PEG Ratio | 82.1 | |||||
PS Ratio | 5.32 | |||||
PB Ratio | 2.51 | |||||
Price-to-Tangible-Book | 2.62 | |||||
Price-to-Free-Cash-Flow | 23.16 | |||||
Price-to-Operating-Cash-Flow | 17.69 | |||||
EV-to-EBIT | 14.21 | |||||
EV-to-Forward-EBIT | 17.4 | |||||
EV-to-EBITDA | 13.48 | |||||
EV-to-Forward-EBITDA | 15.96 | |||||
EV-to-Revenue | 4.78 | |||||
EV-to-Forward-Revenue | 4.76 | |||||
EV-to-FCF | 20.76 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 1.3 | |||||
Price-to-Median-PS-Value | 0.76 | |||||
Price-to-Graham-Number | 1.38 | |||||
| Price-to-Net-Current-Asset-Value | 4.56 | |||||
| Price-to-Net-Cash | 10.2 | |||||
Earnings Yield (Greenblatt) % | 7.04 | |||||
FCF Yield % | 4.5 | |||||
Forward Rate of Return (Yacktman) % | -2.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regeneron Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 13,358.855 | ||
| EPS (TTM) (€) | 34.771 | ||
| Beta | -0.0029 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 35.6 | ||
| 14-Day RSI | 74.66 | ||
| 14-Day ATR (€) | 12.025942 | ||
| 20-Day SMA (€) | 606.775 | ||
| 12-1 Month Momentum % | 18.52 | ||
| 52-Week Range (€) | 470.8 - 699.2 | ||
| Shares Outstanding (Mil) | 102.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regeneron Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-04 | In 181 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-01-29 08:30 | In 176 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-29 | In 175 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 83 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 82 days | ||
| USD 0.940000 Cash Dividend | 2026-08-18 | In 11 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:30 | 612.40 (+0.07%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 612.40 (+0.07%) | ||
| General meeting for 2026 | 2026-06-12 10:30 | 532.30 (+2.07%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:00 | 551.00 (+2.19%) |
Show
Entries
Regeneron Pharmaceuticals Inc Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc(WBO:REGN)'s stock price today?
The current price of WBO:REGN is €662.60. The 52 week high of WBO:REGN is €699.20 and 52 week low is €470.80.
When is next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(WBO:REGN) is 2026-10-28 Est..
Does Regeneron Pharmaceuticals Inc(WBO:REGN) pay dividends? If so, how much?
The Dividend Yield %  of Regeneron Pharmaceuticals Inc(WBO:REGN) is 0.47% (As of Today), Highest Dividend Payout Ratio of Regeneron Pharmaceuticals Inc(WBO:REGN) was 0.08. The lowest was 0.08. And the median was 0.08. The  Forward Dividend Yield % of Regeneron Pharmaceuticals Inc(WBO:REGN) is 0.5%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Regeneron Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers